AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: http://hdl.handle.net/11055/574
Title: High Frequency Spinal Cord Stimulation at 10 kHz for the Treatment of Chronic Pain: 6-Month Australian Clinical Experience
Authors: Russo, Marc
Verrills, Paul
Mitchell, Bruce
Salmon, John
Barnard, Adele
Santarelli, Danielle
Anzca Brief Name: Russo, M
Keywords: spinal cord stimulation
high frequency stimulation
HF10
paraesthesia-free
back pain
leg pain
neuromodulation
Issue Date: May-2016
Citation: 19(4):267-280
Abstract: BACKGROUND: High frequency spinal cord stimulation at 10 kHz (HF10 therapy) represents a prominent advance in spinal cord stimulation (SCS) therapy, having demonstrated enhanced efficacy in patients with back and leg pain and pain relief without paresthesia that is sustained at 24 months post implant. OBJECTIVE: To report on the effectiveness HF10 SCS therapy for a wide range of intractable pain conditions in clinical practice. STUDY DESIGN: Retrospective investigation of 256 patients who trialed HF10 SCS for chronic intractable pain of various etiologies. SETTING: Three Australian pain clinics. METHODS: Two hundred fifty-six patients trialed HF10 SCS with view of a permanent implant if successful. Pain distributions included back + leg, back only, head ± neck, and neck ± arm/shoulder. About 30% of patients had previously failed traditional low-frequency paresthesia-based stimulation, while the remaining cohort were either highly refractory to treatment or not recommended by the pain physician for traditional SCS. Pain scores (numerical pain rating scale - NPRS) and functional outcome measures (Oswestry Disability Index - ODI; and activity tolerance times) were assessed at baseline, post-trial, and at 3 and 6 months post-implant as available in the medical records. RESULTS: Of the 256 patients, 189 (73%) reported a positive trial and were implanted. Patients with back + leg pain demonstrated the highest trial success rate (81%). A mean reduction in pain, among those for whom data were available, of 50% was sustained up to 6 months post-implant across the entire patient population. Sixty-eight percent of patients who failed traditional SCS reported a positive trial and mean pain relief at 6 months was 49% (P < 0.001). An 8.6 point reduction in ODI (21%) at 6 months and improved sitting, standing, and walking tolerances were also reported. LIMITATIONS: As data was collected retrospectively, missing data points were unavoidable; this was primarily due to inconsistent data collection and patients being lost to follow-up. Patient populations were diverse and a control group was not appropriate in this setting. CONCLUSIONS: These retrospective results demonstrate a significant advancement for patients suffering with chronic intractable pain and are consistent with recently published clinical results for HF10 SCS. HF10 SCS appears to be a viable, paresthesia-free alternative to traditional SCS, with high trial success rates, demonstrated effectiveness in a range of pain distributions including those typically difficult to treat with traditional SCS, and the possibility to restore pain control in patients who have previously failed traditional SCS.
URI: http://hdl.handle.net/11055/574
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/27228514
Journal Title: Pain Physician
Type: Journal Article
Affiliates: Hunter Pain Clinic, Broadmeadow, NSW, Australia
Metro Spinal Clinic, South Caulfield, Victoria, Australia
PainCare Multidisciplinary Group, Cottesloe, WA, Australia
Study/Trial: Cohort Study
Appears in Collections:Scholarly and Clinical

Files in This Item:
File Description SizeFormat 
HF10 SCS for the Treatment of Chronic Pain- 6-Month Aust Clinical Experience - 2016 - RUSSO et al (I (ID 54757).pdf
  Restricted Access
703.71 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.